Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy
Key Points:
- A Phase I/II clinical trial (RMC-GI-102) showed that combining daraxonrasib with chemotherapy led to substantial tumor shrinkage and prolonged disease control in patients with metastatic pancreatic cancer who had not received prior treatment.
- The trial reported a 60.7% objective response rate, including 8.2% complete responses, with a median progression-free survival of 12.8 months, nearly doubling the duration seen with standard chemotherapy.
- Daraxonrasib targets the mutated RAS gene, which drives pancreatic cancer growth by keeping the growth signal permanently active; this drug inhibits the active RAS protein and disrupts cancer cell survival signals.
- Side effects were manageable, with common adverse events including rash, diarrhea, fatigue, and chemotherapy-related cytopenia; only 5% of patients discontinued treatment due to daraxonrasib-related side effects.
- A larger phase 3 trial (RASolute-303) is underway to confirm whether these promising early results translate into improved overall survival compared to chemotherapy alone, potentially establishing a new first-line treatment for metastatic pancreatic cancer.